- Home
- AWP vs RGNX Comparison
AWP vs RGNX Comparison
Compare AWP & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWP
- RGNX
- Stock Information
- Founded
- AWP 2007
- RGNX 2008
- Country
- AWP United States
- RGNX United States
- Employees
- AWP N/A
- RGNX N/A
- Industry
- AWP Trusts Except Educational Religious and Charitable
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AWP Finance
- RGNX Health Care
- Exchange
- AWP Nasdaq
- RGNX Nasdaq
- Market Cap
- AWP 352.4M
- RGNX 387.0M
- IPO Year
- AWP N/A
- RGNX 2015
- Fundamental
- Price
- AWP $3.86
- RGNX $7.10
- Analyst Decision
- AWP
- RGNX Strong Buy
- Analyst Count
- AWP 0
- RGNX 9
- Target Price
- AWP N/A
- RGNX $32.89
- AVG Volume (30 Days)
- AWP 331.5K
- RGNX 1.0M
- Earning Date
- AWP 01-01-0001
- RGNX 03-13-2025
- Dividend Yield
- AWP 12.48%
- RGNX N/A
- EPS Growth
- AWP N/A
- RGNX N/A
- EPS
- AWP N/A
- RGNX N/A
- Revenue
- AWP N/A
- RGNX $83,328,000.00
- Revenue This Year
- AWP N/A
- RGNX $285.00
- Revenue Next Year
- AWP N/A
- RGNX N/A
- P/E Ratio
- AWP N/A
- RGNX N/A
- Revenue Growth
- AWP N/A
- RGNX N/A
- 52 Week Low
- AWP $3.06
- RGNX $5.62
- 52 Week High
- AWP $4.20
- RGNX $21.57
- Technical
- Relative Strength Index (RSI)
- AWP 46.56
- RGNX 45.27
- Support Level
- AWP $3.77
- RGNX $7.96
- Resistance Level
- AWP $3.91
- RGNX $8.35
- Average True Range (ATR)
- AWP 0.06
- RGNX 0.67
- MACD
- AWP 0.00
- RGNX 0.03
- Stochastic Oscillator
- AWP 44.44
- RGNX 36.36
About AWP abrdn Global Premier Properties Fund of Beneficial Interest
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.